注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.06.018

摘要/Abstract

摘要： 目的探讨应用注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤(DILI)患者的疗效。方法 2019年12月～2022年8月我院诊治的DILI患者72例,被随机分为对照组36例和观察组36例,分别给予硫普罗宁治疗或谷胱甘肽联合硫普罗宁治疗2～4 w。采用黄嘌呤氧化法检测血清超氧化物歧化酶(SOD)水平,采用硫代巴比妥酸法检测血清丙二醛(MDA)水平,采用二硫基双硝基苯甲酸法检测血清谷胱甘肽过氧化物酶(GSH-Px)水平,采用ELISA法检测血清人血红素氧合酶1(HO-1)、白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)和IL-1β水平。结果在治疗4周末,观察组血清ALT和AST水平分别为(40.6±11.5)U/L和(31.0±2.6)U/L,显著低于对照组【分别为(64.6±13.9)U/L和(63.7±15.3)U/L, P＜0.05】,而两组血清总胆红素和GGT水平无显著性相差【分别为(16.8±3.9)μmol/L和(59.2±13.3)U/L对(20.2±4.2)μmol/L和(60.8±14.7)U/L,P>0.05】;观察组血清SOD、GSH-Px和HO-1水平分别为(82.4±12.7)U/L、(99.8±16.6)U/L和(256.7±20.8)U/L,显著高于对照组【分别为(75.6±10.9)U/L、(80.6±15.4)U/L和(197.5±24.9)U/L,P＜0.05】,而血清MDA水平为(5.1±0.8)μmol/L,显著低于对照组【(6.2±1.3)μmol/L,P＜0.05】;观察组血清IL-6、TNF-α、IL-1β和CRP水平分别为(5.1±1.7)pg/mL、(4.4±1.7)pg/mL、(11.2±4.1)ng/mL和(3.9±2.0)mg/L,均显著低于对照组【分别为(9.7±1.1)pg/mL、(10.2±1.8)pg/mL、(25.3±4.8)ng/mL和(13.6±2.9)mg/L,P＜0.05】。结论应用注射用谷胱甘肽联合硫普罗宁治疗DILI患者可有效改善肝功能水平,可能与其抑制了机体炎症和氧化应激反应有关,值得临床进一步观察。

关键词: 药物性肝损伤, 硫普罗宁, 谷胱甘肽, 治疗

Abstract: Objective The aim of this study was to observe the combination of glutathione and tiopronin in the treatment of patients with drug-induced liver injury (DILI). Methods 72 patients with DILI were enrolled in our hospital between December 2019 and August 2022, and were randomly divided into control (n=36) and observation (n=36) group, receiving tiopronin alone or tiopronin and glutathione combination treatment for two to four weeks. Serum malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were detected by thibabituric acid, xanthine oxidation or dithiobis-nitrobenzoic acid methods, respectively. Serum human heme oxygenase-1 (HO-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), IL-1β and C-reactive protein (CRP) levels were detected by ELISA. Results At the end of treatment, serum ALT and AST levels in the observation group were (40.6±11.5)U/L and (31.0±2.6)U/L, both significantly lower than [(64.6±13.9)U/L and (63.7±15.3)U/L, respectively, P＜0.05] in the control, while there were no significant differences respect to serum bilirubin and GGT levels in the two groups [(16.8±3.9) μmol/L and (59.2±13.3)U/L vs. (20.2±4.2)μmol/L and (60.8±14.7)U/L, respectively, P>0.05]; serum SOD, GSH-Px and HO-1 levels in the observation group were (82.4±12.7)U/L, (99.8±16.6)U/L and (256.7±20.8)U/L, all significantly higher than [(75.6±10.9)U/L, (80.6±15.4)U/L and (197.5±24.9)U/L, respectively, P＜0.05], while serum MDA level was (5.1±0.8)μmol/L, much lower than [(6.2±1.3)μmol/L, P＜0.05] in the control; serum IL-6, TNF-α, IL-1β and CRP levels were (5.1±1.7)pg/mL, (4.4±1.7)pg/mL, (11.2±4.1)ng/mL and (3.9±2.0)mg/L, all significantly lower than [(9.7±1.1)pg/mL, (10.2±1.8)pg/mL, (25.3±4.8)ng/mL and (13.6±2.9)mg/L, respectively, P＜0.05] in the control group. Conclusion The combination of glutathione and tiopronin in the treatment of patients with DILI could effectively improve liver function tests back to normal, which might alleviate body inflammatory and oxidative stress reactions, and warrants further clinical investigation.

Key words: Drug-induced liver injury, Tiopronin, Glutathione, Therapy

杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.

Yang Kaining, Wang Mengmeng, Wang Zhankun, et al. Combination of glutathione and tiopronin in the treatment of patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2023, 26(6): 839-842.

参考文献

[1] Liang D, Guan Y, Zhu J, et al. Global research trends of drug-induced liver injury (DILI) in the past two decades: a bibliometric and visualized study.Ann Palliat Med,2021,10(8):8651-8664.
[2] Li L, Wang H, Jones JW. Sphingolipid metabolism as a marker of hepatotoxicity in drug-induced liver injury. Prostaglandins Other Lipid Mediat,2020,151(12):106484.
[3] Xu Y, Jiang Y, Li Y. Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k/Akt inhibition. Toxicol Res (Camb),2020,9(3):149-157.
[4] 周静,黄海英,李卫国,等.肝胆舒康胶囊联合硫普罗宁治疗非酒精性脂肪肝病的临床研究.现代药物与临床,2020,35(9):1795-1799.
[5] Wen C, Leng Z, Chen Y, et al. Betaine alleviates heat stress-induced hepatic and mitochondrial oxidative damage in broilers. J Poult Sci,2021,58(2):103-109.
[6] 吕厚宽,刘晓晖.异甘草酸镁联合还原型谷胱甘肽对肝细胞癌肝切除患者的应用价值.中国普通外科杂志,2020,29(4):458-465.
[7] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.中华肝脏病杂志,2015,23(11):810-820.
[8] 中华医学会消化病学分会肝胆疾病协作组.急性药物性肝损伤诊治建议(草案) .中华消化杂志, 2007,27(11): 765-767.
[9] Cueto-Sanchez A, Niu H, Campo-Herrera E, et al. Lymphocyte profile and immune checkpoint expression in drug-induced liver injury: An immunophenotyping study. Clin Pharmacol Ther,2021,110(6):1604-1612.
[10] Tang J, Gu J, Chu N, et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. Liver Int,2022,42(8):1803-1813.
[11] 李丹妮,周平.聚乙二醇α-2a干扰素联合硫普罗宁对外出务工慢性乙型肝炎患者疗效及C-Ⅳ、PCⅢ、eGFR水平的影响.中西医结合肝病杂志,2020,30(5):399-401.
[12] 于静,胡琳琳,吴邹钰.硫普罗宁联合双环醇治疗乙型肝炎的效果分析.检验医学与临床,2020,17(24):3660-3662.
[13] Berntssen M, Rosenlund G, Garlito B, et al. Sensitivity ofAtlantic salmon to the pesticide pirimiphos-methyl, present in plant-based feeds. Aquaculture, 2020,16(4):735825.
[14] Elsawy H, Algefare AI, Alfwuaires M, et al. Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells. Biosci Rep, 2020,40(6):686.
[15] 姜晓娜,潘俊杰,于亚男,等.硫普罗宁联合谷胱甘肽治疗对非酒精性脂肪肝患者生化指标的影响.药学实践杂志,2021,39(5):465-467,475.
[16] Du L, Zheng Y, Yang YH, et al. Krill oil prevents lipopolysaccharide-evoked acute liver injury in mice through inhibition of oxidative stress and inflammation. Food Funct,2022,13(7):3853-3864.
[17] Zhang Y, Han Z, Jiang A, et al. Protective effects of pterostilbene on lipopolysaccharide-induced acute lung injury in mice by inhibiting NF-κB and activating Nrf2/HO-1 signaling pathways. Front Pharmacol,2021,29(11):591836.
[18] 王丽惠,张佳祥,刘双平,等.原儿茶酸对刀豆蛋白A所致的免疫性肝损伤小鼠肝组织MDA、NO、SOD和GSH-PX表达的影响.实用肝脏病杂志,2021,24(3):323-326.
[19] Xiang J, Cao K, Dong YT, et al. Lithium chloride reduced the level of oxidative stress in brains and serums of APP/PS1 double transgenic mice via the regulation of GSK3β/Nrf2/HO-1 pathway. Int J Neurosci,2020,130(6):564-573.
[20] 段昕妤,吴凯,朱超慧,等.还原型谷胱甘肽联合多烯磷脂酰胆碱对急性药物性肝损伤患者肝功能、肝纤维化指标及血清炎性因子的影响.现代生物医学进展,2021,21(14):2679-2682.

注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*

Combination of glutathione and tiopronin in the treatment of patients with drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[2]	宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.
[3]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[4]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[5]	曹汴川, 刘梅, 丁苹, 汤玲毓, 郭明贤, 周仙, 袁天茹, 严一凯, 黄富礼, 黄永茂. 格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 801-804.
[6]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[7]	陈雅君, 朱婧, 李璐, 何钦. 标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 835-838.
[8]	王新月, 周莉, 董金玲, 陈煜. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 843-846.
[9]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[10]	刘公攀, 陈涛, 丁志刚, 任明, 郭兴军, 邵存华, 卢建树. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.
[11]	于双杰, 李元元, 毕京峰, 福军亮, 宓余强. ICIs联合TKIs治疗HBV相关肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 891-894.
[12]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.
[13]	青秀, 周沙, 刘斌. HIFU消融联合化疗治疗中晚期肝母细胞瘤小儿5年随访研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 911-914.
[14]	刘明, 王金婷, 杨士彦, 杨位轩, 万元春. ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(6): 915-918.
[15]	古乾权, 陈杰, 邓开. 双镜联合治疗胆囊结石合并肝外胆管结石患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 919-922.